Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma

Phase 1

Recruiting

• Conditions: Solid Tumors or Lymphoma
• Interventions: Biological: IBI363

• Registration Number: NCT05460767
• Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Brief Summary

This study is an open-label, multicenter, phase Ia/Ib study. The study will evaluate the safety, tolerability and preliminary efficacy of IBI363 in subjects with advanced, relapsed or metastatic solid tumors or lymphoma, determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), and thus determine the recommended phase 2 dose (RP2D).

Detailed Description

This study is an open-label, multicenter, phase Ia/Ib study. The study will evaluate the safety, tolerability and preliminary efficacy of IBI363 in subjects with advanced, relapsed or metastatic solid tumors or lymphoma, determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), and thus determine the recommended phase 2 dose (RP2D). The phase Ia part consists of the dose escalation and PD marker exploration part. The phase Ib part consists of the dose expansion part.

Study Timeline

• Study First Submitted: 2022-07-05
• Study First Submitted QC: 2022-07-13
• Study First Posted: 2022-07-15
• Study Start: 2022-08-31
• Status Verified: 2023-12
• Last Update Submitted: 2023-12-24
• Last Update Posted: 2023-12-29
• Primary Completion: 2024-03-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 260

Inclusion Criteria

1. Male or female subjects, ≥ 18 years
2. Histologically or cytologically confirmed, unresectable locally advanced or metastatic solid tumors or lymphomas
3. Subjects who progressed or are intolerant to existing standard therapy or subjects without standard therapy Note: Subjects may have received and failed prior therapy with a PD-1/PD-L1 inhibitor and be considered eligible for this trial.
4. Subjects with at least one measurable lesion according to RECIST v1.1 for solid tumor or Lugano 2014 for lymphoma
5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
6. Expected survival time ≥ 3 months.

Read More

Exclusion Criteria

1. Subjects with history of or known active seizure disorder, brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease.
2. Subjects with active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to first administration of study drug unless adequately treated and considered by the Investigator to be stable.
3. Active uncontrolled bleeding or a known bleeding diathesis.
4. Subjects with massive pleural effusion or massive ascites.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
IBI363	IBI363	Single arm

Primary Outcome Measures

Name	Time	Method
incidence of adverse enents (AE), serious adverse events (SAEs), treatment-emergent AEs (TEAEs) and immune-related AEs (irAEs)	up to 90 days after the last administration	AE is defined as an unexpected medical problem that happens during treatment with a drug or other therapy. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is an important medical event that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. A TEAE will be defined as any new AE that begins, or any pre-existing condition that worsens in severity, after at least 1 dose of study treatment has been administered. irAEs will be assessed.
Number of participants with abnormality in hematology parameters	up to 90 days after the last administration	Blood samples will be collected to evaluate hemoglobin, white blood cell (WBC) count, platelets and coagulation factors including international normalized ratio (INR), activated partial thromboplastin time (aPTT) and prothrombin time (PT)
Number of dose-limiting toxicity (DLT)	21 days during the first 3-week cycle	Incidence of dose-limiting toxicity (DLT) events
Number of participants with abnormality in vital signs	up to 90 days after the last administration	Blood pressure, pulse, respiratory rate, and temperature will be assessed.
Number of participants with abnormality in ECG parameters	up to 90 days after the last administration	12-lead ECG will be obtained using an ECG machine. Participants will be in supine or a semi-recumbent position (about 30 degrees of elevation) and rested for approximately 2 minutes before ECGs are recorded.
Number of participants with abnormality in clinical chemistry parameters	up to 90 days after the last administration	Blood samples will be collected to evaluate sodium, potassium, calcium, magnesium, chloride, glucose, creatinine, urea or blood urea nitrogen (BUN), bicarbonate, amylase, bilirubin, alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total protein, albumin, lactate dehydrogenase and lipase.
Number of participants with abnormality in routine urinalysis parameters	up to 90 days after the last administration	Urine samples will be collected to evaluate specific gravity, leucocyte esterase, nitrite, blood, bilirubin, protein, glucose, ketones and urobilinogen.

Secondary Outcome Measures

Name	Time	Method
maximum concentration (Cmax)	Up to 2 years	PK parameters to be evaluated for IBI363 including maximum concentration (Cmax) will be determined when appropriate.
area under the curve (AUC)	Up to 2 years	PK parameters to be evaluated for IBI363 including area under the curve (AUC) will be determined when appropriate.
clearance (CL)	Up to 2 years	PK parameters to be evaluated for IBI363 including clearance (CL) will be determined when appropriate.
time to response (TTR)	Up to 2 years	To evaluate the preliminary antitumor activity of IBI363
half-life (t1/2) of IBI363	Up to 2 years	PK parameters to be evaluated for IBI363 including half-life (t1/2) will be determined when appropriate.
volume of distribution (V)	Up to 2 years	PK parameters to be evaluated for IBI363 including volume of distribution (V) will be determined when appropriate.
Objective response rate (ORR)	Up to 2 years	To evaluate the preliminary antitumor activity of IBI363
6-month and 1-year PFS rate	Up to 2 years	To evaluate the preliminary antitumor activity of IBI363
duration of response (DoR)	Up to 2 years	To evaluate the preliminary antitumor activity of IBI363
disease control rate (DCR)	Up to 2 years	To evaluate the preliminary antitumor activity of IBI363
progression-free survival (PFS)	Up to 2 years	To evaluate the preliminary antitumor activity of IBI363
Overall survival (OS)	through study completion, an average of 1 year	To evaluate the preliminary antitumor activity of IBI363
6-month and 1-year OS rate	Up to 2 years	To evaluate the preliminary antitumor activity of IBI363
The incidence of ADA and NAb of IBI363	Up to 2 years	Each subject will be tested for anti-drug (IBI363) antibody (ADA), and ADA-positive serum samples will continue to be tested for neutralizing antibodies (NAb).

Trial Locations

Locations (1)

First Affiliated Hospital of Zhejiang University School of Medicine; 🇨🇳 Hangzhou, Zhejiang, China